



## Recent Advances in Protein-Drug Conjugates: From Bioanalytical, Drug Metabolism to Pharmacokinetics

Guest Editor:

**Prof. Dr. Young G. Shin**

College of Pharmacy and  
Institute of Drug Research and  
Development, Chungnam  
National University, Daejeon,  
Republic of Korea

Deadline for manuscript  
submissions:

**closed (15 March 2024)**

### Message from the Guest Editor

Protein–drug conjugates such as antibody–drug conjugates (ADC) have recently received significant attention due to their dramatic clinical efficacies with acceptable toxicity profiles, particularly as novel anticancer drugs. This approach comprises a protein (i.e., monoclonal antibody) conjugated to the cytotoxic payload via a chemical linker directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and, therefore, toxicity. Thus, ADC is one of the most popular platforms but also requires a good balance among various components such as monoclonal antibody, linker, and payload from drug metabolism and pharmacokinetic perspectives. Albumin–drug conjugates (ALDCs) are another good novel platform of choice due to favorable distribution to the tumor as well as a long half-life. ALDCs are also receiving increased attention from the pharmaceutical industry as an alternative approach to overcome various cancers. In addition to protein or linker sides, new payloads are also recently introduced, such as immuno-modulators, molecular glues, and PROTACs for conjugation.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical  
Biology and Phytochemistry,  
University of Münster,  
Corrensstrasse 48, D-48149  
Münster, Germany

## Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## Contact Us

---

*Molecules* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/molecules](http://mdpi.com/journal/molecules)  
[molecules@mdpi.com](mailto:molecules@mdpi.com)  
[X@Molecules\\_MDPI](#)